List view / Grid view

ZYTIGA (abiraterone acetate)



Johnson & Johnson reports 2014 first-quarter results

15 April 2014 | By Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. Domestic sales increased 2.2%. International sales increased 4.5%, reflecting…


ZYTIGA® approved in the EU

11 January 2013 | By Johnson & Johnson

Janssen announced that the EC has approved an extension to the license of the oral, once-daily medication ZYTIGA®...